Samsung Biologics has announced that its U.S. subsidiary, Samsung Biologics America, will buy Human Genome Sciences from GSK. This deal marks Samsung Biologics' first manufacturing facility in the U.S., based in Rockville, Maryland. The site has two large plants with a combined 60,000 liters of capacity for making medicines, and it will continue producing current products. Samsung plans to invest more money to improve the facility as well as expand its capabilities.
The deal, expected to close by the end of Q1 2026, is worth $280 million. Samsung Biologics will keep over 500 employees at the site to maintain operations. This move will aid the company provide more options for clients in both the U.S. and Korea, ensuring that important medicines are available for American patients.
Samsung Biologics has a strong track record of building and operating its facilities on time and is expanding with new projects, including Bio Campus III for research and new types of therapies. With a total of 785,000 liters of manufacturing capacity across five plants, Samsung Biologics is a leader in the industry.
Executive Statement
According to John Rim, CEO and President of Samsung Biologics, this landmark acquisition is a testament to their unwavering commitment to advancing global healthcare and bolstering their manufacturing capabilities in the U.S. The investment will enable us to deepen their collaboration with federal, state, and local stakeholders to best serve their customers and partners while ensuring a reliable and stable supply of life-saving therapeutics. This marks an important step forward in their mission to achieve a better life through biomedicines, and they look forward to building on the legacy of this facility as they welcome experienced colleagues to the Samsung Biologics family and continue delivering innovative solutions that make a meaningful impact.
According to Regis Simard, President, Global Supply Chain, GSK, today's agreement to divest the Rockville manufacturing site to our valued long-term partner, Samsung Biologics, will secure the manufacture of two important medicines on US soil for US patients and further build GSK's supply chain resilience.
